...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Comparison of quality assurance for performance and safety characteristics of the facility for Boron Neutron Capture therapy in Petten/NL with medical electron accelerators.
【24h】

Comparison of quality assurance for performance and safety characteristics of the facility for Boron Neutron Capture therapy in Petten/NL with medical electron accelerators.

机译：在Petten / NL中使用医疗电子加速器对硼中子捕获疗法设施的性能和安全性进行质量保证的比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: The European Council Directive on health protection 97/43/EURATOM requires radiotherapy quality assurance programmes for performance and safety characteristics including acceptance and repeated tests. For Boron Neutron Capture therapy (BNCT) at the High Flux Reactor (HFR) in Petten/NL such a programme has been developed on the basis of IEC publications for medical electron accelerators. RESULTS: The fundamental differences of clinical dosimetry for medical electron accelerators and BNCT are presented and the order of magnitude of dose components and their stability and that of the main other influencing parameter 10B concentration for BNCT patient treatments. A comparison is given for requirements for accelerators and BNCT units indicating items which are not transferable, equal or additional. Preliminary results of in vivo measurements done with a set of 55Mn, 63Cu and 197Au activation foils for all single fields for the four fractions at all 15 treated patients show with < +/- 4% up to now a worse reproducibility than the used dose monitoring systems (+/- 1.5%) caused by influence of hair position on the foil-skull distance. CONCLUSIONS: Despite the more complex clinical dosimetry (because of four relevant dose components, partly of different linear energy transfer (LET)) BNCT can be regulated following the principles of quality assurance procedures for therapy with medical electron accelerators. The reproducibility of applied neutron fluence (proportional to absorbed doses) and the main safety aspects are equal for all teletherapy methods including BNCT.
机译：背景与目的：欧洲理事会关于健康保护的指令97/43 / EURATOM要求放射治疗质量保证计划的性能和安全性，包括接受和重复测试。对于Petten / NL的高通量反应堆（HFR）中的硼中子俘获治疗（BNCT），该程序是根据IEC出版物中有关医用电子加速器的内容开发的。结果：提出了医学电子促进剂和BNCT的临床剂量学的根本区别，以及BNCT患者治疗的剂量成分及其稳定性的大小顺序以及其他主要影响参数10B浓度的顺序。对加速器和BNCT单元的需求进行了比较，以指示不可转让，相等或额外的物品。使用一组55Mn，63Cu和197Au活化箔对所有15名接受治疗的患者的四个部位的所有单个区域进行的体内测量的初步结果显示，迄今为止，再现性<+/- 4％较使用的剂量监测更差头发位置对箔纸头骨距离的影响所导致的系统（+/- 1.5％）。结论：尽管临床剂量学比较复杂（由于四个相关的剂量成分，部分是不同的线性能量转移（LET）），但BNCT仍可按照医用电子促进剂治疗的质量保证程序原则进行调节。对于包括BNCT在内的所有远程治疗方法，中子注量的重现性（与吸收剂量成正比）和主要安全性是相同的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号